Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
54°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
118.45
+0.99 (+0.84%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
18
19
Next >
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
December 15, 2022
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
December 13, 2022
Via
ACCESSWIRE
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
December 12, 2022
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
December 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Merck Announces First-Quarter 2023 Dividend
November 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
November 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
November 21, 2022
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Imago BioSciences, Inc.
November 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
November 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END
Via
FinancialNewsMedia
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
November 07, 2022
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...
Via
FinancialNewsMedia
Exposures
COVID-19
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
November 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Why Investors Are Suddenly Excited About Vaxcyte
October 31, 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via
MarketBeat
Exposures
COVID-19
Can Big Data Make Patient Care More Personalized And Effective?
October 28, 2022
It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets...
Via
TheNewswire.com
Merck Stock Price Rose as the Company Raised Its Full-Year Outlook Due to the Success of Keytruda
October 27, 2022
Merck & Co Inc (NYSE:MRK) A rise in demand for blockbuster cancer treatment Keytruda and human papillomavirus vaccination Gardasil contributed to Merck & Co Inc (NYSE: MRK) higher-than-expected sales...
Via
PressReach
Topics
Intellectual Property
Exposures
Intellectual Property
Merck Beats Expectations for the Third Quarter as Sales of the COVID-19 Tablet Are Partially Offset by Keytruda
October 27, 2022
Merck stock was trading at $100.91 as of 09:49 AM EDT. After reporting stronger-than-anticipated financial results for the third quarter of 2022, Merck (NYSE:MRK) saw its pre-market trading price...
Via
PressReach
Exposures
COVID-19
Merck Announces Third-Quarter 2022 Financial Results
October 27, 2022
From
Merck & Co., Inc.
Via
Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
October 26, 2022
From
Merck & Co., Inc.
Via
Business Wire
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
October 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
October 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat: Week in Review 10/17-10/21
October 22, 2022
Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
October 18, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
October 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.